Abstract
Safety standards for vaccines are very high given they are used among healthy persons for prevention rather than treatment and it is often difficult to predict who will be exposed to and develop a particular disease, if they are not immune. There are a broad range of activities conducted by the federal government, the private sector and academic investigators to optimize the safety of vaccines and identify, characterize and minimize vaccine adverse reactions when they occur.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Department of Health and Human Services (HHS), Department of Veterans Affairs, and Department of Defense, A Comprehensive Review of Federal Vaccine Safety Programs and Public Health Activities. 2008.
Food and Drug Administration, Guidance for Industry: Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product. 1999.
Food and Drug Administration. Vaccine Product Approval Process. 2015; Available from: https://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicslicenseapplicationsblaprocess/ucm133096.htm.
Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP). 2017; Available from: https://www.cdc.gov/vaccines/acip/index.html.
Ellenberg, S.S., Safety considerations for new vaccine development. Pharmacoepidemiol Drug Saf, 2001. 10(5): p. 411–5.
Centers for Disease Control and Prevention (CDC). Vaccine Adverse Event Reporting System (VAERS). 2017; Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html.
Chen, R.T., et al., The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ, 2000. 78(2): p. 186–94.
Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD). 2017; Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html.
Baggs, J., et al., The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics, 2011. 127 Suppl 1: p. S45–53.
Kohl, K.S., et al., Advances in Patient Safety The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization, in Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology), K. Henriksen, et al., Editors. 2005, Agency for Healthcare Research and Quality (US): Rockville (MD).
Salmon, D., et al., Success of program linking data sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance. Health Aff (Millwood), 2012. 31(11): p. 2518–27.
Baker, M.A., et al., Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Vaccine, 2013. 31 Suppl 10: p. K98–112.
Institute of Medicine, in Adverse Effects of Vaccines: Evidence and Causality, K. Stratton, et al., Editors. 2012, National Academies Press (US): Washington (DC).
Halsey, N.A., et al., Algorithm to assess causality after individual adverse events following immunizations. Vaccine, 2012. 30(39): p. 5791–8.
Aliabadi, N., J.E. Tate, and U.D. Parashar, Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines. Clin Microbiol Infect, 2016. 22 Suppl 5: p. S128–s135.
Yih, W.K., et al., Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med, 2014. 370(6): p. 503–12.
Parashar, U.D., et al., Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines. Vaccine, 2015.
Halsey, N.A., et al., The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. Vaccine, 2015. 33: p. F1–F67.
Salmon, D.A., et al., Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet, 2013. 381(9876): p. 1461–8.
Seligman, S.J., Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine, 2014. 32(44): p. 5769–75.
Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep, 1996. 45(28): p. 603–6.
Angel, J.B., et al., Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med, 1998. 129(2): p. 104–6.
Wood, R.A., et al., An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics, 2008. 122(3): p. e771–7.
Wood, R.A., R. Setse, and N. Halsey, Irritant skin test reactions to common vaccines. J Allergy Clin Immunol, 2007. 120(2): p. 478–81.
Tozzi, A.E., et al., Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine, 2013. 31(44): p. 5041–6.
World Health Organization, Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed. 2018: World Health Organization.
99th Congress (1985-1986), National Childhood Vaccine Injury Act. 1986.
Institute of Medicine (US) Committee on Review of Priorities in the National Vaccine Plan, The Safety of Vaccines and Vaccination Practices, in Priorities for the National Vaccine Plan. 2010, National Academies Press (US).
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Dudley, M.Z. et al. (2018). Monitoring Vaccine Safety. In: The Clinician’s Vaccine Safety Resource Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-94694-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-94694-8_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-94693-1
Online ISBN: 978-3-319-94694-8
eBook Packages: MedicineMedicine (R0)